Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus delbrueckii bulgaricus
- Development stage
- Unknown
- Lead developer
- Marlex Pharmaceuticals
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Vaginal
01
Overview
Lactobacillus delbrueckii bulgaricus is a Gram-positive, rod-shaped lactic acid bacterium utilized as a probiotic and live biotherapeutic. Historically recognized as a yogurt starter culture, it has been developed for pharmaceutical applications, including a previously marketed product by Marlex Pharmaceuticals for the treatment of fever blisters and cold sores. Its therapeutic effects are mediated through the modulation of the gut microbiome, production of short-chain fatty acids (SCFAs) like acetate, and regulation of the host immune system. Clinical research indicates potential benefits in reducing serum triglycerides and improving antioxidant capacity in conditions such as gestational diabetes and obesity, although its efficacy in weight reduction remains a subject of ongoing study.
- Other names
- Lactobacillus bulgaricusL. bulgaricusLactobacillus delbrueckii subsp. bulgaricus
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on lactobacillus delbrueckii bulgaricus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus delbrueckii bulgaricus.